CEO of Tema ETFs recommends investing in weight loss stocks for potentially large profits

Are you looking to capitalize on the latest trends in the finance world? Well, look no further than the world of weight loss stocks! Tema ETFs has been at the forefront of this movement, with their GLP-1, Obesity & Cardiometabolic ETF (HRTS) seeing a 26% increase since its launch in November.

But what sets Tema ETFs apart from the rest? Founder and CEO Maurits Pot believes that the success of the weight loss trade is not just based on hype. In fact, the companies they invest in are exploring innovative approaches beyond just weight loss. Pot envisions a future where GLP-1 is not just used for weight loss, but for other diseases as well.

Related:  AI demand helps SK Hynix overcome losses in the first quarter as a supplier to Nvidia

Some of Tema ETFs’ top holdings include Eli Lilly, the manufacturer of Mounjaro, which has seen a 57% increase in stock value this year, and Novo Nordisk, the maker of Ozempic and Wegovy, which has seen a 38% increase. These companies are paving the way for a new era in healthcare and weight loss solutions.

But what about the affordability of these treatments? Pot is confident that the price of GLP-1s will decrease significantly in the next few years, making them more accessible to a wider range of patients. With potential pricing dropping from $12,000 to $6,000 a year, or $500 a month, these treatments may become a more viable option for many.

Related:  Top Stocks including Costco Hit Buy Points on IBD Screen

At Extreme Investor Network, we strive to bring you the latest insights and opportunities in the finance world. Stay ahead of the curve with our expert analysis and cutting-edge information. Don’t just follow the trends, invest in the future with us. Join Extreme Investor Network today and start making smarter financial decisions.

Source link